This trial is active, not recruiting.

Condition allergic rhinitis
Sponsor University of California, Los Angeles
Collaborator Merck Sharp & Dohme Corp.
Start date January 2008
End date December 2009
Trial size 25 participants
Trial identifier NCT00915447, FAU # 441329-ZC-77586, IRB # 07-10-025


The purpose of this study is to measure the effects of allergens and/or diesel exhaust particles in the nose to learn more about allergic responses in individuals with cat allergic rhinitis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Individuals with cat allergic rhinitis, yet without routine cat exposure

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: 1. Age 18 to 65 years old. 2. Positive prick (epicutaneous) skin test to standardized cat with a wheal equal to or greater than 3 mm and with a surrounding flare. 3. Ability to give informed consent. Exclusion Criteria: 1. Pregnancy or breast-feeding. (Pregnancy and the period during breast feeding can affect nasal congestion and be a confounder in this regard.) 2. Systemic corticosteroid use within the previous three months or anytime during the challenge protocol. 3. Topical nasal corticosteroid use within the past month or anytime during the challenge protocol. 4. Systemic antihistamines or decongestant use within past two weeks or anytime during the trial. 5. Chronic sinusitis or chronic non-allergic rhinitis. 6. Use of reserpine. 7. Cigarette smoking within the past year or during the challenge protocol 8. Use of topical nasal antihistamines, chromoglycolates (chromolyn, Cromlon®), decongestants or non-steroidal anti-inflammatory agents (NSIADS) within the preceding week or anytime during the challenge protocol. 9. Present or treatment within the past 10 years with allergy immunotherapy (injections). 10. Present or past treatment with anti-IgE therapy. 11. Any unusual exposure to air pollutants (e.g., working as a diesel mechanic) that, in the opinion of the investigators, might compromise the individual's ability to participate in the study. 12. Living arrangement where the subject has a cat dwelling within the subject's habitation. 13. Any serious heart, lung, neurological or kidney disease that in the opinion of the investigators would impair the individual's ability to participate in the study. 14. Use of asthma-required medications.

Additional Information

Official title Diesel Exhaust Particles and Leukotriene Production
Principal investigator Marc Riedl, M.D., M.S.
Trial information was received from ClinicalTrials.gov and was last updated in August 2010.
Information provided to ClinicalTrials.gov by University of California, Los Angeles.